Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies mig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mult Scler
Hauptverfasser: Wurm, Hannah, Attfield, Kate, Iversen, Astrid KN, Gold, Ralf, Fugger, Lars, Haghikia, Aiden
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Case Report and Clinical Commentary
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7502978/
https://ncbi.nlm.nih.gov/pubmed/32762494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458520943791
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge